Dynavax Technologies Corporation stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Dynavax Technologies Corporation stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Dynavax Technologies Corporation do? Business model and key facts
Get the full picture of Dynavax Technologies Corporation: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees (FY): 405
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Stocks related to Dynavax Technologies Corporation
Selected based on industry alignment and relative market positioning.
Events and news impacting Dynavax Technologies Corporation stock
Earnings, coporate decisions and industry developments that can affect the share price.
Dynavax Technologies Corporation fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
